CRISPR Therapeutics (CRSP) Tops Q3 EPS by 58c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q3 EPS of ($1.41), $0.58 better than the analyst estimate of ($1.99).

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Medtronic completes $550 million Scientia Vascular acquisition
• The Lovesac Company (LOVE) Tops Q1 EPS by 29c